While pursuing different autoimmune diseases for Cosentyx (secukinumab), Novartis AG has presented more long-term data which the company hopes will consolidate the blockbuster's leading position in its core indication of psoriasis.
The Swiss major has heralded "first-of-its-kind long-term data" showing that Cosentyx provided sustained improvements for up to 2.5 years in...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
